ANNE TSAO to Drug Interactions
This is a "connection" page, showing publications ANNE TSAO has written about Drug Interactions.
Connection Strength
0.014
-
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.
Score: 0.014